My mom, (aged 77, Adenocarcinoma NSCLC, Stage 4, EGFR and ALK negative) was diagnosed in 2014, underwent VATS and pleurodesis, followed by 6 cycles of Carboplatin & Alimta, Alimta maintenance, Tarceva (for just a couple of months) and is now on Keytruda for her stage 4, lung cancer treatment. Her PDL-1 expression was over 70%.
The following is her first PET-CT result following 4 cycles of Keytruda (really 3 cycles as the 4th infusion was less than a week before the scan). I'm looking for assistance to understand this report and possible options as we set up time with her oncologist to discuss her recommendations.
Thanks as always!
- Mixed response to therapy compared to previous study 6/21/2018
- There is slight decrease in the scattered intense FDG uptake noted along the thickened pleura and in a dominant lung nodule in the left lower lobe. Many of the pleural based lesions demonstrate some calcifications, query: prior pleurodesis?
- The bilateral, supraclavicular lymph nodes, right paratracheal, left hilar lymph nodes, left para-aortic and left retrocrural lymph nodes are no longer measurable without any FDG uptake. The findings are compatible with favorable response.
- Interval new widespread foci of intense FDG uptake noted throughout the visualized bones in predominantly sclerotic lesions. The findings are compatible with progression of metasis to the bones.